Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
Klotz
Laurence
L
Division of Urology, University of Toronto, and Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada. laurence.klotz@sunnybrook.ca
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D001707:Biopsy, Needle; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D009367:Neoplasm Staging; D019370:Observation; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D020266:Radiotherapy, Conformal; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016896:Treatment Outcome
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen